KCNH2 and invasive carcinoma: Hence, consistent with our in vivo findings, aberrant HERG1 expression may confer a proliferative advantage to the cells carrying this alteration and the acquisition of invasive potential, thus favouring (i) progression of precancerous lesions to invasive carcinoma in early stages of tumourigenesis, and (ii) the acquisition of a truly invasive and metastatic potential in late stages during HNSCC progression, facilitating tumours to grow faster and with increased aggressiveness, which ultimately leads to disease progression.